EAN 2025 | Reflecting on EAN 2025: advancing migraine treatment
Messoud Ashina, MD, PhD, Danish Headache Center, Copenhagen, Denmark, highlights the significant interest in migraine treatment at the 2025 EAN Congress. Prof. Ashina mentions several teaching courses and sessions focused on the treatment of migraine, and highlights his presentation on anti-PACAP treatment. This interview took place at the 11th Congress of the European Academy of Neurology (EAN 2025) in Helsinki, Finland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
During this EAN meeting, I can tell you that migraine, in particular treatment of migraine, was one of the central focus areas during the Congress. This was shown also in exhibition area with different companies involved in migraine field. And also when we talk in general about the number of people who attended the satellite symposia, the different satellites focusing on migraine, they were full house...
During this EAN meeting, I can tell you that migraine, in particular treatment of migraine, was one of the central focus areas during the Congress. This was shown also in exhibition area with different companies involved in migraine field. And also when we talk in general about the number of people who attended the satellite symposia, the different satellites focusing on migraine, they were full house. We’re talking about teaching course, many people. Special session for oral presentation for headache was also full. People were standing, not even enough space to see. And I was also proud that one of these important sessions about the breakthroughs, the new potential new treatments in future in migraine was also very well attended. And I had an honor to present results of anti-PACAP, monoclonal antibody study, which was published last year, again showing that there is a great interest among neurologists, general neurologists in migraine, and particularly migraine treatment and future treatment. So this is good news for neurologists practicing headache medicine.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
MA has received personal fees as a consultant or speaker from AbbVie, Astra Zeneca, Eli Lilly, GlaxoSmithKline, Lundbeck, Pfizer, and Teva. MA also serves as an Associate Editor of Brain and an Associate Editor of The Journal of Headache and Pain.
